StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) company profile

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.67−0.98 (-6.69%)

Close on Nov 17, 2026Market cap $334.99MP/E –Yield –

About Lyell Immunopharma

Pharmaceutical Preparations, SIC 2834

Lyell is a clinical-stage biotechnology company that develops autologous chimeric antigen receptor T-cell therapies for cancer patients. The company focuses on hematologic malignancies and solid tumors, modifying patient immune cells to target cancerous tissues. Its lead product candidate is rondecabtagene autoleucel, a dual-targeting CD19 and CD20 cell therapy in clinical trials for large B-cell lymphoma. The company also develops LYL273, a cell therapy candidate targeting guanylyl cyclase C for patients with advanced metastatic colorectal cancer. Lyell's therapies target cancer patients with relapsed, refractory, or advanced malignancies.

The company conducts clinical trials across the United States, Canada, and Australia, with one pivotal trial enrolling patients at about twenty-five sites. Lyell operates a dedicated manufacturing facility called the LyFE Manufacturing Center to produce cell therapies for clinical trials. In addition, its global licensing rights for LYL273 cover worldwide territories excluding mainland China, Hong Kong, Macau, and Taiwan. The provided text does not state the location of the company's headquarters.

Summary of the business section of Lyell Immunopharma's latest annual report, written by StockData.

Company profile

Company

Legal name
Lyell Immunopharma, Inc.
Headquarters
South San Francisco, CA
Address
201 Haskins Way 94080
Phone
(650) 695-0677
Website
lyell.com
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Mateo, California

Stock & identifiers

Ticker
LYEL
Exchange
Nasdaq
IPO date
Jun 21, 2021
Shares outstanding
25M, Aug 3, 2026
Public float
$129.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Jun 2, 2025
SEC CIK
1806952
CUSIP
55083R203
ISIN
US55083R2031
FIGI
BBG00RNXFN14
Share class FIGI
BBG00RNXFN23
EIN
83-3006753

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Lynn SeelyPresident and CEO, Director63,354
Gary K. LeeChief Scientific Officer16,091
Veronica Sanchez BulisVP, Corporate Controller14,383
Stephen J. HillChief Operating Officer16,728
Jarrad Mattieu AguirreChief Medical Officer19,857
David ShookChief Medical Officer20,423
Smital ShahChief Fin. and Bus. Officer–
Mark A. MeltzGeneral Counsel–
Charles W. NewtonChief Financial Officer25,306
Matthew LangChief Business Officer162,500
Richard KlausnerDirector190,557
Sumant RamachandraDirector10,000
Elizabeth G. NabelDirector–
Otis W. BrawleyDirector1,782
William Jl RieflinDirector–
Mark BachledaDirector–
Cathy FriedmanDirector16,818

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.22M$9.64M$2.01M$44–
FY2024
Elizabeth Homans
$0$0$1.61M$18–
FY2024
Lynn Seely MD
$1.50M-$3.24M$1.61M$18–
FY2023
Elizabeth Homans
$0$0$3.21M$56–
FY2023
Lynn Seely MD
$2.65M-$7.94M$3.21M$56–
FY2022$12.12M-$7.44M$4.00M$45–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Lynn Seely, M.D.
President, Chief Executive Officer and Director
$690.17K$186.81K$2.91M$414.00K$23.74K$4.22M+182%
Stephen Hill
Chief Operating Officer
$529.47K$62.27K$1.18M$291.50K$9.59K$2.08M+55%
Gary Lee, Ph.D.
Chief Scientific Officer
$520.02K$62.27K$1.09M$260.00K$6.79K$1.94M+48%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 21, 2021
Offer price
$17.00
Securities offered
25,000,000
Gross proceeds
$425.00M
Exchange
Nasdaq
First trading day
Jun 18, 2021
First-day close
$16.20-4.7%
Lock-up ends (est.)
Dec 15, 2021

“The initial public offering price of our common stock is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?